GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer
Posted by: DrugsNews on: 14 Dec, 2009
- In: Drugs News| News
- Comment!
GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer
LONDON and PHILADELPHIA, Dec. 11 /PRNewswire/ — In a clinical
study, women with an aggressive form of breast cancer experienced a
median survival of 14 months when treated with an investigational
combination of TYKERB® (lapatinib) plus…
Read more about GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer
| Indian Pharmacy! Looking for Generic Medications? Quality Drugs at affordable prices! Reliable Indian Pharmacy www.IndianPharmacy.org |
#1 Canadian Pharmacy Online! The Lowest Prices from Canadian Drugstore! Various payments, secure shopping, worldwide shipping! www.CanadianPharmacyLtd.org |
What are the Drugs-Review websites?
The Drugs-Review websites are NOT but will be your number one stop for all the latest news, comment and pharmaceutical industry information.
Related posts:
- GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival In Patients With Advanced Breast Cancer
- Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
- Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
